|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weigelt B, Peterse JL and van't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Espaillat MP, Shamseddine AA, Adada MM,
Hannun YA and Obeid LM: Ceramide and sphingosine-1-phosphate in
cancer, two faces of the sphinx. Transl Cancer Res. 4:484–499.
2015.
|
|
5
|
Wymann MP and Schneiter R: Lipid
signalling in disease. Nat Rev Mol Cell Biol. 9:162–176. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xia P, Gamble JR, Wang L, Pitson SM,
Moretti PA, Wattenberg BW, D'Andrea RJ and Vadas MA: An oncogenic
role of sphingosine kinase. Curr Biol. 10:1527–1530. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Limaye V, Li X, Hahn C, Xia P, Berndt MC,
Vadas MA and Gamble JR: Sphingosine kinase-1 enhances endothelial
cell survival through a PECAM-1-dependent activation of PI-3K/Akt
and regulation of Bcl-2 family members. Blood. 105:3169–3177. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maceyka M, Sankala H, Hait NC, Le Stunff
H, Liu H, Toman R, Collier C, Zhang M, Satin LS, Merrill AH Jr, et
al: SphK1 and SphK2, sphingosine kinase isoenzymes with opposing
functions in sphingolipid metabolism. J Biol Chem. 280:37118–37129.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Igarashi N, Okada T, Hayashi S, Fujita T,
Jahangeer S and Nakamura S: Sphingosine kinase 2 is a nuclear
protein and inhibits DNA synthesis. J Biol Chem. 278:46832–46839.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu H, Toman RE, Goparaju SK, Maceyka M,
Nava VE, Sankala H, Payne SG, Bektas M, Ishii I, Chun J, et al:
Sphingosine kinase type 2 is a putative BH3-only protein that
induces apoptosis. J Biol Chem. 278:40330–40336. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Q, Li J, Li G, Li Y, Xu C, Li M, Xu G
and Fu S: Prognostic significance of sphingosine kinase 2
expression in non-small cell lung cancer. Tumor Biol. 35:363–368.
2014. View Article : Google Scholar
|
|
12
|
French KJ, Schrecengost RS, Lee BD, Zhuang
Y, Smith SN, Eberly JL, Yun JK and Smith CD: Discovery and
evaluation of inhibitors of human sphingosine kinase. Cancer Res.
63:5962–5969. 2003.PubMed/NCBI
|
|
13
|
Malavaud B, Pchejetski D, Mazerolles C, De
Paiva GR, Calvet C, Doumerc N, Pitson S, Rischmann P and Cuvillier
O: Sphingosine kinase-1 activity and expression in human prostate
cancer resection specimens. Eur J Cancer. 46:3417–3424. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li W, Yu CP, Xia JT, Zhang L, Weng GX,
Zheng HQ, Kong QL, Hu LJ, Zeng MS, Zeng YX, et al: Sphingosine
kinase 1 is associated with gastric cancer progression and poor
survival of patients. Clin Cancer Res. 15:1393–1399. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van Brocklyn JR, Jackson CA, Pearl DK,
Kotur MS, Snyder PJ and Prior TW: Sphingosine kinase-1 expression
correlates with poor survival of patients with glioblastoma
multiforme: Roles of sphingosine kinase isoforms in growth of
glioblastoma cell lines. J Neuropathol Exp Neurol. 64:695–705.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kohno M, Momoi M, Oo ML, Paik JH, Lee YM,
Venkataraman K, Ai Y, Ristimaki AP, Fyrst H, Sano H, et al:
Intracellular role for sphingosine kinase 1 in intestinal adenoma
cell proliferation. Mol Cell Biol. 26:7211–7223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Le Scolan E, Pchejetski D, Banno Y, Denis
N, Mayeux P, Vainchenker W, Levade T and Moreau-Gachelin F:
Overexpression of sphingosine kinase 1 is an oncogenic event in
erythroleukemic progression. Blood. 106:1808–1816. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu SQ, Su YJ, Qin MB, Mao YB, Huang JA
and Tang GD: Sphingosine kinase 1 promotes tumor progression and
confers malignancy phenotypes of colon cancer by regulating the
focal adhesion kinase pathway and adhesion molecules. Int J Oncol.
42:617–626. 2013.PubMed/NCBI
|
|
19
|
Liu G, Zheng H, Zhang Z, Wu Z, Xiong H, Li
J and Song L: Overexpression of sphingosine kinase 1 is associated
with salivary gland carcinoma progression and might be a novel
predictive marker for adjuvant therapy. BMC Cancer. 10:4952010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guan H, Song L, Cai J, Huang Y, Wu J, Yuan
J, Li J and Li M: Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim
pathway and contributes to apoptosis resistance in glioma cells.
PLoS One. 6:e199462011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Akao Y, Banno Y, Nakagawa Y, Hasegawa N,
Kim TJ, Murate T, Igarashi Y and Nozawa Y: High expression of
sphingosine kinase 1 and S1P receptors in chemotherapy-resistant
prostate cancer PC3 cells and their camptothecin-induced
up-regulation. Biochem Biophys Res Commun. 342:1284–1290. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kawamori T, Osta W, Johnson KR, Pettus BJ,
Bielawski J, Tanaka T, Wargovich MJ, Reddy BS, Hannun YA, Obeid LM
and Zhou D: Sphingosine kinase 1 is up-regulated in colon
carcinogenesis. FASEB J. 20:386–388. 2006.PubMed/NCBI
|
|
23
|
Pchejetski D, Golzio M, Bonhoure E, Calvet
C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissié J,
Malavaud B and Cuvillier O: Sphingosine kinase-1 as a chemotherapy
sensor in prostate adenocarcinoma cell and mouse models. Cancer
Res. 65:11667–11675. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sarkar S, Maceyka M, Hait NC, Paugh SW,
Sankala H, Milstien S and Spiegel S: Sphingosine kinase 1 is
required for migration, proliferation and survival of MCF-7 human
breast cancer cells. FEBS Lett. 579:5313–5317. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Datta A, Loo SY, Huang B, Wong L, Tan SS,
Tan TZ, Lee SC, Thiery JP, Lim YC, Yong WP, et al: SPHK1 regulates
proliferation and survival responses in triple-negative breast
cancer. Oncotarget. 5:5920–5933. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luo HJ, Chen X, Tu G, Wang J, Wu CY and
Yang GL: Therapeutic application of ultrasound-guided 8-gauge
mammotome system in presumed benign breast lesions. Breast J.
17:490–497. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan X, Zhou T, Tai YH, Wang C, Zhao J, Cao
Y, Chen Y, Zhang PJ, Yu M, Zhen C, et al: Elevated expression of
CUEDC2 protein confers endocrine resistance in breast cancer. Nat
Med. 17:708–714. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goldhirsch A, Wood W, Coates A, Gelber R,
Thürlimann B and Senn HJ: Panel members: Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Paget S: The distribution of secondary
growths in cancer of the breast. Cancer Metastasis Rev. 8:98–101.
1889.
|
|
31
|
Fidler IJ: The pathogenesis of cancer
metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang W, Goswami S, Sahai E, Wyckoff JB,
Segall JE and Condeelis JS: Tumor cells caught in the act of
invading: Their strategy for enhanced cell motility. Trends Cell
Biol. 15:138–145. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yao G, He P, Chen L, Hu X, Gu F and Ye C:
MT1-MMP in breast cancer: Induction of VEGF-C correlates with
metastasis and poor prognosis. Cancer Cell Int. 13:982013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yan LX, Huang XF, Shao Q, Huang MY, Deng
L, Wu QL, Zeng YX and Shao JY: MicroRNA miR-21 overexpression in
human breast cancer is associated with advanced clinical stage,
lymph node metastasis and patient poor prognosis. RNA.
14:2348–2360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Skobe M, Hawighorst T, Jackson DG, Prevo
R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K and Detmar
M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast
cancer metastasis. Nat Med. 7:192–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim HS, Yoon G, Ryu JY, Cho YJ, Choi JJ,
Lee YY, Kim TJ, Choi CH, Song SY, Kim BG, et al: Sphingosine kinase
1 is a reliable prognostic factor and a novel therapeutic target
for uterine cervical cancer. Oncotarget. 6:26746–26756. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shu X, Wu W, Mosteller RD and Broek D:
Sphingosine kinase mediates vascular endothelial growth
factor-induced activation of ras and mitogen-activated protein
kinases. Mol Cell Biol. 22:7758–7768. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ruckhäberle E, Rody A, Engels K, Gaetje R,
von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U,
Karn T and Kaufmann M: Microarray analysis of altered sphingolipid
metabolism reveals prognostic significance of sphingosine kinase 1
in breast cancer. Breast Cancer Res Treat. 112:41–52. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hait NC, Sarkar S, Le Stunff H, Mikami A,
Maceyka M, Milstien S and Spiegel S: Role of sphingosine kinase 2
in cell migration toward epidermal growth factor. J Biol Chem.
280:29462–29469. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yamanaka M, Shegogue D, Pei H, Bu S,
Bielawska A, Bielawski J, Pettus B, Hannun YA, Obeid L and
Trojanowska M: Sphingosine kinase 1 (SPHK1) is induced by
transforming growth factor-beta and mediates TIMP-1 up-regulation.
J Biol Chem. 279:53994–54001. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Donati C, Cencetti F, De Palma C, Rapizzi
E, Brunelli S, Cossu G, Clementi E and Bruni P: TGFbeta protects
mesoangioblasts from apoptosis via sphingosine kinase-1 regulation.
Cell Signal. 21:228–236. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stayrook KR, Mack JK, Cerabona D, Edwards
DF, Bui HH, Niewolna M, Fournier PG, Mohammad KS, Waning DL and
Guise TA: TGFβ-mediated induction of SphK1 as a potential
determinant in human MDA-MB-231 breast cancer cell bone metastasis.
Bonekey Rep. 4:7192015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li J, Guan HY, Gong LY, Song LB, Zhang N,
Wu J, Yuan J, Zheng YJ, Huang ZS and Li M: Clinical significance of
sphingosine kinase-1 expression in human astrocytomas progression
and overall patient survival. Clin Cancer Res. 14:6996–7003. 2008.
View Article : Google Scholar : PubMed/NCBI
|
